Skip to main content
Tiziana Life Sciences Ltd logo

Tiziana Life Sciences Ltd — Investor Relations & Filings

Ticker · TLSA ISIN · BMG889121031 LEI · 984500769407C5E46F42 US Professional, scientific and technical activities
Filings indexed 460 across all filing types
Latest filing 2026-05-28 Regulatory Filings
Country BM Bermuda
Listing US TLSA

About Tiziana Life Sciences Ltd

https://www.tizianalifesciences.com/

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company focused on developing innovative immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's core strategy involves utilizing alternative drug delivery routes, such as intranasal administration, to modulate the immune system. Its lead clinical candidate, foralumab (TZLS-401), is the only fully human anti-CD3 monoclonal antibody being investigated for neurological conditions. Foralumab is in clinical development for the treatment of Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS), Alzheimer's disease, Amyotrophic Lateral Sclerosis (ALS), and Multiple System Atrophy (MSA). The company's pipeline also includes an anti-IL-6 receptor monoclonal antibody (TZLS-501) for potential application in lung diseases.

Recent filings

Filing Released Lang Actions
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 90% confidence The document is a Form 6-K ‘Report of Foreign Private Issuer’ filed pursuant to the Securities Exchange Act. It contains a corporate presentation announcement and includes an exhibit press release, but does not include substantive financial statements or a full annual/interim report. Form 6-K filings are miscellaneous regulatory updates by foreign private issuers and do not fit any other more specific category. Therefore, it falls under the general ‘Regulatory Filings’ category.
2026-05-28 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer (Tiziana Life Sciences LTD) under the Securities Exchange Act. It furnishes an exhibit (a press release) but does not contain substantive financial statements or management analysis itself. As a short regulatory submission (non-financial report) used to disclose corporate developments, it best fits the Regulatory Filings category.
2026-05-21 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 90% confidence The document is an SEC Form 6-K (“Report of Foreign Private Issuer”) filed under the Securities Exchange Act of 1934, which serves as a regulatory report to furnish an attached press release. It contains no substantive financial statements or earnings data, nor does it announce management/board changes, capital transactions, dividends, or any other specialized filing category. It is therefore best classified under “Regulatory Filings” (RNS).
2026-05-19 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K “Report of Foreign Private Issuer” filed under the U.S. Securities Exchange Act containing a furnished press release as Exhibit 99.1. Form 6-K filings are routine regulatory reports of foreign private issuers rather than full financial reports or meeting materials. Under the taxonomy, such general regulatory filings that don’t fit other specific categories are classified as Regulatory Filings (RNS).
2026-05-14 English
20-F - Tiziana Life Sciences Ltd (0001723069) (Filer)
Annual Report FY 2025
2026-05-01 English
6-K - Tiziana Life Sciences Ltd (0001723069) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It announces the publication of positive preclinical data in a bioRxiv preprint and includes a press release as Exhibit 99.1. The document is relatively short (3033 characters) and primarily serves as an announcement of the publication of scientific data rather than containing detailed financial statements or comprehensive report content. It does not contain actual financial data or detailed management discussion. The document explicitly states that the information is furnished and not filed, indicating it is an announcement rather than a full report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2026-04-16 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.